Search
Carboplatin Treatment Options
A collection of 1669 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
1213 - 1224 of 1669
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Los Angeles, California +4 locations
Conditions: Solid Cancers
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Terminated
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are eligible for the study: untreated, treated and requiring further treatment, or treated and failed and for whom adding R1507 represents a suitable treatment for their disease. All regimens will first t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Tucson, Arizona +7 locations
Conditions: Neoplasms
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Buffalo, New York +2 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
Completed
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with histologically or cytologically documented inoperable, locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Birmingham, Alabama +41 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Terminated
This is a research study to determine if administering carboplatin at a slower rate when re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity reaction will decrease the frequency and severity of future hypersensitivity reactions.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
Terminated
This study is intended to evaluate the role of paclitaxel poliglumex and carboplatin in the treatment of unresectable Stage III non-small cell lung cancer along with radiation therapy in a multi-institutional trial. Consolidation chemotherapy with paclitaxel poliglumex and carboplatin will follow the completion of chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2016
Locations: University of California, San Francisco, San Francisco, California +7 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Ixabepilone + Carboplatin Metastatic Breast Cancer
Completed
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2016
Locations: Hematology Oncology Associates, Phoenix, Arizona +58 locations
Conditions: Metastatic Breast Cancer
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Completed
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2016
Locations: Teva Investigational Site 002, Detroit, Michigan +3 locations
Conditions: Cancer
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2016
Locations: Medical College of Georgia, Augusta, Georgia +13 locations
Conditions: NSCLC
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: City of Hope National Medical Center, Duarte, California +54 locations
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Completed
Primary objective:
* Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.
Secondary objective:
* Compare overall survival of participants treated with these regimens.
* Compare the toxic effects (including cardiac) of these regi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/26/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +41 locations
Conditions: Breast Neoplasms
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
Completed
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/26/2016
Locations: Site Reference ID/Investigator# 117416, Scottsdale, Arizona +4 locations
1213 - 1224 of 1669